Opko Health (OPK) Receives News Sentiment Score of 0.09
News articles about Opko Health (NASDAQ:OPK) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Opko Health earned a coverage optimism score of 0.09 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.9425887355745 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Opko Health, Inc. (OPK) Tights Shoes to Boost up Long-Term Obligations – Stock News Stop (stockmarketstop.com)
- OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy – GlobeNewswire (press release) (globenewswire.com)
- Today’s Research Reports on Trending Tickers: BioLineRx Ltd. and Opko Health, Inc. (finance.yahoo.com)
- Why OPKO Health (OPK) Could Be Positioned for a Slump (zacks.com)
Opko Health (OPK) opened at $4.99 on Thursday. Opko Health has a 52 week low of $4.50 and a 52 week high of $12.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66.
Opko Health (NASDAQ:OPK) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The firm had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The firm’s revenue for the quarter was down 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. research analysts expect that Opko Health will post -0.27 earnings per share for the current year.
OPK has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Thursday, October 26th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $16.00 price target on shares of Opko Health in a research note on Monday, September 25th. Jefferies Group reiterated a “hold” rating and issued a $6.50 price target (down from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. BidaskClub upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Saturday, September 23rd. Finally, J P Morgan Chase & Co lowered shares of Opko Health from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $12.00 to $7.00 in a research note on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $13.97.
In related news, major shareholder Opko Health, Inc. purchased 655,738 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were acquired at an average price of $3.05 per share, for a total transaction of $2,000,000.90. Following the purchase, the insider now owns 6,678,752 shares in the company, valued at $20,370,193.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Phillip Md Et Al Frost purchased 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The stock was bought at an average price of $6.01 per share, for a total transaction of $90,150.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $18,444,395.51. The disclosure for this purchase can be found here. Insiders have bought a total of 1,052,238 shares of company stock worth $4,374,796 over the last 90 days. 40.19% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/29/opko-health-opk-receives-news-sentiment-score-of-0-09.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.